Evidence map›Paper›PMID 40534727›Full record

ArticleFrontiers in computational neuroscience2025

A new method for community-based intelligent screening of early Alzheimer's disease populations based on digital biomarkers of the writing process.

Shuwu Li, Kai Li, Jiakang Liu, Shouqiang Huang, Chen Wang, Yuting Tu, Bo Wang, Pengpeng Zhang, Yuntian Luo, Yanli Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in computational neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuwu Li *School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Kai Li *School of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Jiakang Liu *School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Shouqiang HuangSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Chen WangSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Yuting TuSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Bo WangSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Pengpeng ZhangSchool of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Yuntian LuoSchool of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Yanli ZhangSchool of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Tong ChenDepartment of Neurology, Second Medical Center of Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In response to the shortcomings of the current Alzheimer's disease (AD) early populations assessment, which is based on neuropsychological scales with high subjectivity, low accuracy of repeated measurements, tedious process and dependence on physicians, it was found that digital biomarkers based on the writing process can effectively characterize the cognitive deficits of patients with mild cognitive impairment (MCI) due to AD. Methods: This study designed a digital writing assessment paradigm, extracted dynamic handwriting and image data during the paradigm assessment process, and analyzed digital biomarkers of the writing process to assess subjects' cognitive functions. A total of 72 subjects, including 34 health controls (HC) and 38 MCI due to AD, were enrolled in this study. Results: Their combined screening efficacy of digital biomarkers based on the MCI writing process due to AD populations having an area under curve (AUC) of 0.918, and a confidence interval (CI) of 0.854-0.982, was higher than the Montreal Cognitive Assessment Scale (AUC = 0.859, CI = 0.772-0.947) and the Mini-mental State Examination Scale (AUC = 0.783, CI = 0.678-0.888). Conclusion: Therefore, digital biomarkers based on the writing process can characterize and quantify the cognitive function of MCI due to AD populations at a fine-grained level, which is expected to be a new method for intelligent screening and early warning of early AD populations in a community-based physician-free setting.

Indexed as

Alzheimer’s diseasedigital biomarkersearly warningmild cognitive impairmentwriting

Identifiers

PMID40534727
PMCPMC12174119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.